Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron's stock price has experienced a significant decline of over 30% in the past six months. Key events impacting the stock price include a court ruling on Eylea biosimilar, Q1 2025 earnings miss, Eylea headwinds, acquisition of 23andMe's consumer genetics business, antitrust case victory against Amgen, Fujifilm partnership for manufacturing expansion, and a clinical supply agreement with Immuneering.

Information detailing the demand seasonality for Regeneron products is limited. The pharmaceutical and biotech industries can exhibit seasonal patterns, with some companies showing stronger patterns due to advertising and PR effects. Historically, some pharmaceutical stocks have shown strong seasonal patterns, particularly in the summer months. Regeneron's revenue trends show fluctuations, with annual revenue increasing from $13.117 billion in 2023 to $14.202 billion in 2024, and quarterly revenue for March 31, 2025, at $3.029 billion. The demand for specific products like Eylea can be impacted by factors such as competition from biosimilars and funding gaps at patient assistance foundations.

Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions. The company operates within the Healthcare sector and the Biotechnology industry, specifically in Pharmaceutical Preparations. Regeneron's major products and product candidates address a wide range of therapeutic areas, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Key marketed products include EYLEA, Dupixent, Libtayo, Praluent, Kevzara, Evkeeza, Inmazeb, and Arcalyst. Regeneron develops its products using proprietary technologies such as Trap and VelociSuite platforms.

Regeneron Pharmaceuticals operates globally, with offices in 12 countries and clinical trials underway in more than 50 countries. Its primary operations are in the United States and the Rest of the World. The company's headquarters are in Tarrytown, New York, U.S. In North America, Regeneron has offices in various U.S. states and Canada. In Europe, Regeneron has offices in the Netherlands, Ireland, the United Kingdom, Spain, Italy, Germany, and France. The company also operates manufacturing units in the U.S. and Ireland. Regeneron-invented medicines are available in over 100 countries.

Regeneron is recognized as a leading biotechnology company with a strong reputation for translating scientific discoveries into approved treatments. Successful drug development and approvals, acquisitions, legal victories, and financial performance can impact its reputation. The acquisition of 23andMe's consumer genetics business, with Regeneron's prioritization of privacy, security, and ethical use of customer data, could impact public perception. The successful antitrust case against Amgen could enhance its reputation. Missed earnings and declining sales of key products can indirectly affect investor and public confidence.

Regeneron Pharmaceuticals is primarily owned by institutional shareholders, with approximately 84.75% of the company owned by institutional shareholders, 37.25% by Regeneron insiders, and 0.00% by retail investors. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Fmr Llc, JPMorgan Chase & Co., State Street Corp., Capital International Investors, Geode Capital Management, Llc, Dodge & Cox, Franklin Resources Inc., and T. Rowe Price Group, Inc. The largest individual Regeneron Pharmaceuticals shareholder is Sanofi, owning 36.52 million shares, representing 33.82% of the company.